Search This Blog

Sunday, February 10, 2019

Lilly drops Hanmi BTK inhibitor

Eli Lilly and Co. (NYSE:LLY) discontinued from its pipeline a Bruton’s tyrosine kinase (Btk) inhibitor it had licensed from Hanmi Pharmaceutical Co. Ltd. (KSE:128940).
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)